Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients

Frontiers in Immunology

Volumn 7, Issue DEC, 2016, Pages

  Toor, Salman M ^a   Khaja, Azharuddin Sajid Syed ^a,b   El Salhat, Haytham ^c   Bekdache, Omar ^d   Kanbar, Jihad ^d   Jaloudi, Mohammed ^d   Elkord, Eyad ^a,b,e  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b HAMAD BIN KHALIFA UNIVERSITY   (Qatar)

^c Al Noor Hospital   (United Arab Emirates)

^d TAWAM HOSPITAL   (United Arab Emirates)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Circulation; Colorectal cancer; Myeloid cells; Neutrophils; Tumor microenvironment

Indexed keywords

ARGINASE 1; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; REGIONAL METASTASIS; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

EID: 85009360798     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00560     Document Type: Article

References (41)

1. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer (2009) 125(8):1747-54. doi: 10.1002/ijc.24439
2. Corthay A. Does the immune system naturally protect against cancer? Front Immunol (2014) 5:197. doi:10.3389/fimmu.2014.00197
3. Chaudhary B, Abd Al Samid M, al-Ramadi BK, Elkord E. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther (2014) 14(7):931-45. doi:10.1517/14712598.2014.900539
4. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 67(1):425. doi:10.1158/0008-5472.CAN-06-3037
5. Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res (1987) 47(1):100-5.
6. Toor SM, Elkord E. Myeloid-derived suppressor cells. eLS (2015) 1-8. doi:10.1002/9780470015902.a0024245
7. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9(3):162-74. doi:10.1038/nri2506
8. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother (2012) 61(8):1155-67. doi:10.1007/s00262-012-1294-5
9. Brandau S, Moses K, Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol (2013) 23(3):171-82. doi:10.1016/j.semcancer.2013.02.007
10. Stanojevic I, Miller K, Kandolf-Sekulovic L, Mijuskovic Z, Zolotarevski L, Jovic M, et al. A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. Int Immunol (2016) 28(2):87-97. doi:10.1093/intimm/dxv053
11. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 7:12150. doi:10.1038/ncomms12150
12. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci (2013) 70(20):3813-27. doi:10.1007/s00018-013-1286-4
13. Chioda M, Peranzoni E, Desantis G, Papalini F, Falisi E, Solito S, et al. Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev (2011) 30(1):27-43. doi:10.1007/s10555-011-9268-1
14. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12(4):253-68. doi:10.1038/nri3175
15. Moses K, Brandau S. Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol (2016) 28(2):187-96. doi:10.1016/j.smim.2016.03.018
16. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 124(12):5466-80. doi:10.1172/JCI77053
17. Zilio S, Serafini P. Neutrophils and granulocytic MDSC: the Janus god of cancer immunotherapy. Vaccines (Basel) (2016) 4(3):ii:E31. doi:10.3390/vaccines4030031
18. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother (2010) 59(10):1593-600. doi:10.1007/s00262-010-0855-8
19. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer (2016) 16(7):431-46. doi:10.1038/nrc.2016.52
20. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1319:47-65. doi:10.1111/nyas.12469
21. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin (2016) 66(1):7-30. doi:10.3322/caac.21332
22. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut (2016). doi:10.1136/gutjnl-2015-310912
23. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res (2009) 29(7):2727-37.
24. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 182(8):4499-506. doi:10.4049/jimmunol.0802740
25. Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ, et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol (2012) 18(25):3303-9. doi:10.3748/wjg.v18.i25.3303
26. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One (2013) 8(2):e57114. doi:10.1371/journal.pone.0057114
27. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 166(1):678-89. doi:10.4049/jimmunol.166.1.678
28. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2009) 58(1):49-59. doi:10.1007/s00262-008-0523-4
29. Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res (2014) 2014:879897. doi:10.1155/2014/879897
30. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 182(10):6562-8. doi:10.4049/jimmunol.0803831
31. Florcken A, Takvorian A, Singh A, Gerhardt A, Ostendorf BN, Dorken B, et al. Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. Immunol Lett (2015) 168(2):260-7. doi:10.1016/j.imlet.2015.10.001
32. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 69(4):1553-60. doi:10.1158/0008-5472.CAN-08-1921
33. Shipp C, Speigl L, Janssen N, Martens A, Pawelec G. A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. Cell Mol Life Sci (2016) 73(21):4043-61. doi:10.1007/s00018-016-2278-y
34. Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol (2013) 190(2):794-804. doi:10.4049/jimmunol.1202088
35. Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, et al. TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res (2015) 21(16):3771-82. doi:10.1158/1078-0432.CCR-14-3145
36. Rodriguez PC, Quiceno DG, Ochoa AC. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2007) 109(4):1568-73. doi:10.1182/blood-2006-06-031856
37. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 64(16):5839-49. doi:10.1158/0008-5472.CAN-04-0465
38. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. l-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003) 24(6):302-6. doi:10.1016/S1471-4906(03)00132-7
39. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 125(9):3356-64. doi:10.1172/JCI80005
40. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol (2003) 16(4):376-88. doi:10.1097/01.MP.0000062859.46942.93
41. Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, et al. New criteria for histologic grading of colorectal cancer. Am J Surg Pathol (2012) 36(2):193-201. doi:10.1097/PAS.0b013e318235edee